Bivalirudin
Muscle/RecoveryFDA-approved direct thrombin inhibitorEstablished
FDA-approved bivalent direct thrombin inhibitor used with PCI. IV bolus plus infusion per labeled weight-based regimen; hospital use only.
For research use only.
Key Facts
- CAS
- 128270-60-0
- Molecular Weight (MW)
- 2180.3 g/mol
- Half-life
- ~25 minutes (normal renal function)
- Unit
- mcg
- Administration Route
- Intravenous
- Frequency
- Continuous IV infusion during procedure
- Last updated
- 8/23/2026
- Targets
- Thrombin (factor IIa)
Overview
FDA-approved bivalent direct thrombin inhibitor used with PCI. IV bolus plus infusion per labeled weight-based regimen; hospital use only.
Protocol
- Dosage Range
- 0.75 mg/kg bolus followed by 1.75 mg/kg/hour infusion
- Frequency
- Continuous IV infusion during procedure
- Cycle
- Per procedure
- Administration Route
- Intravenous
- Reconstitution Guide
- Reconstitute with sterile water for injection per package insert
Science
Mechanism of Action
Reversible direct thrombin inhibitor that binds both the catalytic site and exosite 1 of thrombin, inhibiting clot-bound and circulating thrombin.
Targets
Thrombin (factor IIa)
Studies
- ACUITY / HORIZONS-AMI bivalirudin trials— Journal/year not available
Benefits
Periprocedural anticoagulationShort half-life after infusion stop
Potential Side Effects
- Bleeding
- Back pain
- Nausea
- Hypotension
References
- FDA label — AngiomaxExternal link · Year —